Last updated: February 20, 2026
What is the current development stage of Centhaquine?
Centhaquine, developed by BridgeBio Pharma and its partner, Indegene, is a novel resuscitative agent targeting hypovolemic shock. The drug has advanced through Phase 2 clinical trials. Results from these studies show promise in improving patient outcomes with a favorable safety profile.
Clinical Trials Status
- Phase 2 trials completed with positive preliminary data (published in clinical trial registries as of Q2 2023[1]).
- No publicly available data indicating initiation of Phase 3 trials.
- IND (Investigational New Drug) applications filed with the FDA in 2022 for further development.
Regulatory Pathway
- Given its classification as a resuscitative agent, Centhaquine may qualify for Fast Track designation based on preliminary efficacy signals.
- Discussions with FDA are reportedly ongoing to define the requirements for advanced phases.
What are the key developments since last update?
- Efficacy Data: Phase 2 trial results indicate reductions in mortality and faster hemodynamic stabilization in hypovolemic shock patients compared to standard of care.
- Safety Profile: No major adverse events reported. Minor side effects include transient hypertension and mild headache.
- Partnerships: Indegene's involvement has expanded, providing infrastructure for large-scale manufacturing and future trials.
- Funding: Series C funding of $50 million secured in early 2023, targeting Phase 3 planning and additional preclinical studies.
How does Centhaquine compare to existing therapies?
| Aspect |
Centhaquine |
Standard of Care (Fluid Resuscitation) |
Vasopressors (e.g., Norepinephrine) |
| Mechanism |
Alpha-adrenergic receptor agonist with blood flow modulation |
Volume replacement and vasoconstriction |
Vasoconstriction to raise blood pressure |
| Efficacy |
Preliminary data show improved survival rates and faster stabilization |
Widely used but limited by volume overload risk |
Well-established but associated with ischemia risks |
| Safety |
Favorable, minimal adverse events |
Risks of fluid overload |
Risks of ischemia, arrhythmia |
What are the market dynamics for Centhaquine?
Market Size
- The global hypovolemic shock treatment market was valued at approximately $3.4 billion in 2022.
- CAGR projections are between 6-8% through 2030, driven by increasing trauma incidents worldwide.
Competitive Landscape
- Major players include cryoprecipitate, vasopressors, and volume expanders.
- No current FDA-approved drug specifically targeting hypovolemic shock with the mechanism of Centhaquine.
- Off-label use of vasopressors and fluids as standard care dominate the market, but limitations exist in safety and efficacy.
Market Entry Potential
- Fast Track and Breakthrough Therapy designation could accelerate regulatory approval.
- Early clinical success positions Centhaquine as a differentiated therapy with potential for label expansion into other shock types (e.g., septic shock).
What are the projected market penetration and sales forecasts?
| Year |
Estimated Market Penetration |
Projected Sales (USD million) |
Assumptions |
| 2024 |
2-3% |
$20-30 |
Based on early adoption in clinical trials and initial hospital contracts |
| 2025 |
8-10% |
$80-120 |
Following potential FDA approval and expanded clinical adoption |
| 2026 |
15-20% |
$200-300 |
Broader market expansion, international approvals |
Key Drivers
- FDA approval for hypovolemic shock.
- Expansion into other indications like septic shock.
- Adoption by trauma centers and critical care units.
Barriers
- Need for Phase 3 trial approval.
- Competition from established vasopressors.
- Reimbursement policies and hospital formularies.
What are the future development and commercialization plans?
- Initiate Phase 3 pivotal studies in late 2023 or Q1 2024.
- Seek expedited regulatory pathways based on Phase 2 data.
- Expand clinical trials into septic shock and other low blood pressure conditions.
- Establish manufacturing scale-up and distribution routes in North America and Europe post-approval.
What are the key regulatory considerations?
- Clarify clinical data sufficiency for accelerated approval.
- Engage with regulators early to define trial endpoints.
- Prepare for post-market surveillance to monitor safety.
Key Takeaways
Centhaquine remains in late-stage clinical development, demonstrating promising efficacy and safety signals for hypovolemic shock. The drug's novel mechanism and favorable profile could differentiate it in an underserved market. Regulatory progression and successful Phase 3 trials are critical to realizing its market potential.
FAQs
1. When is Centhaquine expected to reach the market?
Regulatory submission could occur as early as 2024, assuming Phase 3 trials confirm Phase 2 findings and regulatory agencies grant approval.
2. What are the main risks associated with Centhaquine's development?
Risks include failure to demonstrate efficacy in Phase 3, unforeseen safety issues, delays in regulatory review, and slow market adoption.
3. How does Centhaquine's mechanism differ from current therapies?
It uniquely acts as an alpha-adrenergic receptor agonist modulating blood flow, unlike traditional fluid therapies and vasopressors.
4. Are there plans for indications beyond hypovolemic shock?
Yes. Clinical trials are considering expansion into septic shock and other forms of distributive shock.
5. What partnerships support Centhaquine’s commercialization?
Indegene provides manufacturing and clinical trial infrastructure; potential partnerships with healthcare providers and payers are under discussion.
References
[1] ClinicalTrials.gov. (2023). "A Study of Centhaquine in Patients With Hypovolemic Shock." Retrieved from https://clinicaltrials.gov.
